Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), retaining the price target of $86.00.
Sam Slutsky has given his Buy rating due to a combination of factors related to CG Oncology, Inc.’s strong clinical trial performance and the promising potential of their lead candidate, cretosimogene. The data from the ongoing Phase 3 BOND-003 trial has been particularly encouraging, with cretosimogene showing a significant complete response rate in high risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The therapy’s efficacy is highlighted by a 75.7% any-time complete response rate, which is notably higher than rates observed with currently approved treatments. Additionally, the absence of severe treatment-related adverse events positions cretosimogene as a potentially safer alternative in this patient population.
Moreover, the upcoming presentation of new 12-month data at a prestigious medical conference suggests a strong vote of confidence in the ongoing research and its relevance to current medical practice. This event could further validate the drug’s clinical benefits and enhance its profile within the medical community. The company’s recent successful IPO, raising significant funds, combined with a fully enrolled pivotal trial, underscores CG Oncology’s financial stability and the anticipated timely delivery of topline data. These strategic advantages reinforce Slutsky’s optimistic outlook on the company’s stock, meriting a Buy recommendation.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CGON in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
CG Oncology, Inc. (CGON) Company Description:
Read More on CGON:
- CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- Five new option listings and one option delisting on March 12th
- CG Oncology announces first patient dosed in PIVOT-006 Phase 3 trial
- CG Oncology initiated with an Overweight at Cantor Fitzgerald
- CG Oncology initiated with an Outperform at LifeSci Capital
